Key result
β-blocker use in patients with pulmonary hypertension was not associated with a significant difference in mortality (OR 1.13; 95% CI 0.69-1.82) compared to non-use.
Why the study?
Does β-blocker use affect mortality or clinical worsening in patients with pulmonary hypertension?
Cohort (n=508)
Does β-blocker use affect mortality or clinical worsening in patients with pulmonary hypertension?
Odds Ratio: 1.13 (95% CI 0.69–1.82)
Beta-blocker use in pulmonary hypertension does not significantly impact survival or clinical worsening, though it may be associated with reduced exercise capacity.
No takes yet. Share an insight, caveat, or question.
Does not support β-blocker use or avoidance in pulmonary hypertension; leaves open need for randomized trials.
Bandyopadhyay et al. (2015) conducted a cohort in Pulmonary hypertension (n=508). β-blockers vs. Never used β-blockers was evaluated on All-cause mortality (OR 1.13, 95% CI 0.69-1.82). β-blocker use in patients with pulmonary hypertension was not associated with a significant difference in mortality (OR 1.13; 95% CI 0.69-1.82) compared to non-use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: